After a patient became ill with a potential drug-induced liver injury, Pfizer announced it would discontinue the development of danuglipron, an orally administered experimental treatment for weight management.
To date, the FDA has not approved a pill form for weight loss. Not only is an oral weight-loss drug more appealing to consumers, but pills do not require cold storage and would make the distribution of the medication easier.
Click here to read the entire article.